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ABSTRACT
Group B Streptococcus (GBS) is a leading cause of
neonatal sepsis and meningitis in high-income settings
and is associated with high rates of neonatal mortality
and morbidity. There is now increasing evidence to
suggest that there is a high GBS disease burden in
resource-limited countries, and it is therefore critically
important to identify suitable and practical preventive
strategies. In Europe and North America, intrapartum
antibiotic prophylaxis (IAP) has led to a dramatic
reduction of early-onset GBS disease. However, the
methods for identifying pregnant women who should
receive IAP and how to reduce late-onset GBS disease are
not without controversy and are challenging for most sub-
Saharan African countries. GBS vaccines are approaching
phase III trials but are still under development. This
review aims to explore the current evidence related to
strategies for reducing invasive GBS disease in an African
setting, the development of a GBS vaccine and whether
preventative measures against GBS disease can be
practically implemented.
INTRODUCTION
Worldwide, under-ﬁve mortality has fallen from
12.7 million in 1990 to 6.3 million in 2013.1 2
However, progress needs to be made to reduce
mortality in the ﬁrst month of life, particularly in
resource-limited settings where neonatal deaths
accounted for 44% of all under-ﬁve mortality in
2013.3 In Africa, the neonatal mortality rate (31
per 1000 live births) is almost 4–5 times higher
than that of the Americas (8 per 1000 live births)
and Europe (6 per 1000 live births).3 Bacterial
infection (sepsis, meningitis, pneumonia) is a
leading cause of 2.9 million global neonatal deaths
worldwide.4 Implementing strategies to reduce pre-
ventable infection-related neonatal deaths by 2030
to meet the WHO Sustainable Development Goal
is a global health priority.
Group B Streptococcus (GBS) is a leading cause
of neonatal sepsis and meningitis in high-income
countries and is associated with high rates of
mortality and morbidity.5 6 There is increasing
evidence that the burden of invasive GBS disease in
low–middle-income settings is underappreciated,
particularly in Africa.7 8 Prevention of neonatal
invasive GBS disease may therefore have a consider-
able impact on under-ﬁve mortality.
The use of intrapartum antibiotic prophylaxis
(IAP) has been associated with an 80% reduction in
early-onset GBS disease (EOD: 0–6 days of life);9
however, GBS remains a leading cause of severe
neonatal infection. The ineffectiveness of IAP in
protecting against late-onset disease (LOD: 7–
89 days of life), combined with a high incidence of
EOD in preterm babies (1.0 per 1000 live births),
is a contributing factor.9–11 The evaluation of IAP
as a strategy for the prevention of EOD has largely
been undertaken in high-income settings,12 13 and
there is paucity of data on its suitability and practi-
cality in resource-limited settings, where there are
additional constraints, such as the lack of routine
access to antenatal and intrapartum care, especially
in rural settings. WHO predicts that the proportion
of live births that occur in sub-Saharan Africa will
continue to increase.3 Strategies to reduce the
burden of invasive GBS disease and consequently
under-ﬁve mortality in resource-limited settings is a
public health priority.
In this review, we summarise the pathogenesis of
GBS colonisation and explore the current evidence
related to reducing invasive GBS disease, the devel-
opment of a GBS vaccine and whether preventative
measures against invasive GBS disease can be put
into practice in resource-limited countries.
PATHOGENESIS
GBS is a Gram-positive bacterium, and there are 10
serotypes based on their capsular polysaccharide
composition (Ia, Ib, II–IX). The polysaccharide
capsule is a major virulence factor contributing to
bacterial evasion of phagocytic clearance.10
Serotype III is the most common invasive isolate
and accounts for 30–50% of EOD and majority of
LOD.13 14 Other putative virulence factors include
haemolysin, C5a peptidase and serine protease, but
their role in disease causation remains to be
determined.15
EOD occurs following acquisition of GBS by the
fetus or newborn from their rectovaginally colo-
nised mother. Though 30–70% of the newborns of
GBS colonised women are themselves colonised at
birth, only 1–3% go on to develop EOD.12 13 16
Infection of the fetus can occur either by invasion
of amniotic ﬂuid following prolonged rupture of
membranes (PROM) or through direct acquisition
during birth.10 GBS can invade through macro-
scopically intact membranes possibly through
microtears of the amniotic sac.17 GBS β-haemolysin
promotes lung epithelial cell invasion, leading to
invasion into blood vessels.6 18 Hence, inhalation
of infected amniotic ﬂuid or genital secretions can
cause bloodstream invasion, sepsis and meningi-
tis.18 Disease progression is rapid, with 90% of
EOD presenting within 24 hours of delivery, and
frequently already manifest at birth.10 This, along
with the failure of chlorhexidine vaginal douches
during labour to reduce EOD,19 suggests that most
EODs commence in utero.
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In contrast, the pathogenesis of LOD is uncertain, and the
risk factors and mode of GBS acquisition by the neonate are less
well deﬁned.20 In LOD, GBS may be acquired horizontally via
hospital, community or environmental contacts. Breast milk as a
source of GBS in LOD has also been postulated.21–24 The role
of maternal rectovaginal colonisation and whether there are
other sources of GBS acquisition contributing to LOD require
further study.10
Greater knowledge of the true rate of maternal GBS carriage
and neonatal disease remains critical; in particular, the contribu-
tion of in utero GBS to both preterm labour and stillbirth will
provide a broader insight into the total burden. Furthermore,
the disease-causing serotypes in different resource-limited set-
tings need to be investigated, and new whole-genome sequen-
cing approaches applied to investigate the relationship between
invasive GBS and carriage isolates.10
MATERNAL CARRIAGE OF GBS AND THE IMPACT OF HIV
The main reservoir for GBS is in the large intestine and the
lower genital tract.25 Rectovaginal colonisation by GBS is
dynamic and can be transient, intermittent or persistent.26
Certain factors also favour the transmission of GBS from
mother to infant, including maternal colonisation, density of
colonisation and PROM.10 GBS bacteriuria (found in 2–7% of
pregnant women)27 28 is an indicator for heavy genital tract col-
onisation and is associated with a higher risk of chorioamnioni-
tis, EOD and LOD.29 In addition, virulence of the organism,
particularly of the ST17 genotype, may favour transmis-
sion.10 14 30 Factors that appear to reduce transmission and/or
invasive disease are exposure to intrapartum antibiotics, elective
caesarean section in the absence of labour and high maternal
GBS serotype-speciﬁc capsular antibodies.11 31
Studies based upon vaginal-rectal swabs both in both high-
income and low–middle-income countries (LMICs) have shown
that 10–40% of women are rectovaginally colonised by GBS
during pregnancy.10 A review of GBS carriage by Stoll et al32 in
low-income countries showed 19% GBS carriage in sub-Saharan
African women, while country-speciﬁc studies in Africa showed
carriage rates of 28.4% in South Africa,26 21.2% in Malawi,33
23% in Tanzania34 and 22% in the Gambia.35
Although maternal HIV infection has not been associated
with higher prevalence of GBS colonisation,36 a study in
Malawi showed a direct relationship between CD4+ count and
GBS carriage, with the highest GBS carriage prevalence in
HIV-infected women with CD4 count >500 cells/mm3.33
Reduced GBS carriage at lower CD4 counts may be due to the
competitive exclusion of GBS by ecological changes in the
microbial ﬂora and the increased presence of bacterial vaginosis
and anaerobes.33 Natural maternal capsular and protein anti-
body concentrations against GBS were found to be lower in
HIV-infected South African women, which may also increase
the vulnerability of HIV-exposed infants to GBS EOD and
LOD.37 This has been reﬂected in invasive GBS disease inci-
dence in South Africa, which showed a 2.25-fold greater inci-
dence in HIV-exposed compared with HIV-unexposed infants.36
INTRAVENOUS INTRAPARTUM ANTIBIOTIC STRATEGY TO
PREVENT EARLY-ONSET GBS DISEASE
As neonates with GBS EOD are often already septic at birth,
with rapid progression of disease, a strong focus has been
placed on a secondary preventative strategy to treat at-risk
mothers in labour.10
Mechanism of action of IAP
Given that maternal rectovaginal colonisation is associated with
EOD, IAP aims to reduce the vertical transmission of GBS from
mother to baby by decreasing the colony count at time of deliv-
ery, and also to achieve an effective level of antibiotic in the
fetal circulation.38 Achieving adequate level of antibiotic in the
amniotic ﬂuid may directly protect the neonate against EOD by
preventing the proliferation of GBS in utero.38 39 Clinical trials
in the 1980s demonstrated that IAP reduced the incidence of
early neonatal GBS disease and has formed the basis of IAP
strategy.40 41 A Cochrane review highlighted a statistically signiﬁ-
cant reduction in the early-onset neonatal GBS disease following
IAP compared with no treatment, where in industrialised coun-
tries the number needed to treat to beneﬁt was 25 (95% CI 14
to 100).42
Choice of antibiotic and duration of administration
Globally, GBS remains fully susceptible to β-lactams,43 with ben-
zylpenicillin10 or ampicillin6 most commonly administered.
Erythromycin and vancomycin have been used; however, their
efﬁcacy has not been measured in controlled trials, and the
ability of these antibiotics to achieve bactericidal levels in fetal
circulation and amniotic ﬂuid is uncertain.6 44–46
The optimal duration of IAP to reduce vertical GBS transmis-
sion has also been debated.6 While the Center for Disease
Control (CDC) recommends a minimum duration of 4 hours
between IAP administration and delivery,6 47 several studies have
suggested that the duration of antibiotics may be reduced from
4 hours to 1–2 hours prior to delivery.38 48 49 Indeed, benzylpe-
nicillin levels in cord blood have been shown to exceed the
minimum inhibitory concentration for GBS as early as 1 hour
after maternal administration.38
Identifying those women who require IAP
Two common approaches are used to identify pregnant women
who should receive IAP: universal screening and a risk-based
strategy. More recently, rapid diagnostic tests have been
developed.
Universal screening strategy
All pregnant women in the third trimester of pregnancy (ideally
35–37 weeks gestation) are offered screening for GBS colonisa-
tion. This method is recommended by the CDC and is practised
widely throughout the USA. Those identiﬁed as GBS carriers
are treated with antibiotics during labour. Women with GBS
bacteriuria during the current pregnancy or a previous infant
with invasive GBS disease also receive IAP, without the need for
screening.6 As a result, the incidence of GBS EOD has declined
dramatically, from 1.7 cases per 1000 live births in the early
1990s6 to 0.27 cases per 1000 live births by 2014.50
Risk-based approach
Several risk factors are associated with increased risk of EOD in
the newborn, including preterm labour, PROM >18 hours,
intrapartum fever >38°C, GBS bacteriuria in the mothers
during the current pregnancy and previous sibling with invasive
GBS disease.51 Several countries adopt a strategy to implement
IAP when some or all of these risks are identiﬁed.
The UK Royal College of Obstetricians and Gynaecologists
and the National Institute for Health and Care Excellence do
not recommend routine bacteriological screening of all pregnant
women,11 although if GBS is detected on an incidental vaginal
swab or urine culture then IAP is recommended.11 This reﬂects
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the view that the incidence of EOD will not reduce any further
with the introduction of universal screening for GBS in preg-
nancy; the incidence of EOD in the UK under the risk-based
approach is 0.5/1000, which is similar to that of the USA,
which employs universal screening.11 51 Recently published sur-
veillance data, however, indicate a small but possible rise in the
incidence of EOD (per 1000 live births) in European countries,
including from 0.30 in 1991 to 0.41 in 2010 in the UK,52 and
from 0.11 in 1987 to 0.19 in 2011 in the Netherlands.53
Rapid diagnostic testing during labour
More recently, novel rapid methods to augment or replace trad-
itional microbiological methods to identify GBS have emerged.
Rapid real-time PCR tests demonstrated sensitivity from 62.5%
to 100% and speciﬁcity from 84.6% to 100% compared with
enriched GBS cultures.51 Di Renzo et al51 argue that this
method could prove superior to risk-based approach or univer-
sal screening if undertaken when a woman is in labour as those
who are current carriers of GBS are at most risk of passing GBS
to their babies will be identiﬁed. Direct antigen detection tests
are rapid and inexpensive, but not sufﬁciently sensitive for diag-
nosis.51 The loop-mediated isothermal ampliﬁcation method to
identify GBS could combine many of the advantages of PCR
tests with the relative simplicity of antigen detection tests;54
however, this is still in development. In resource-limited set-
tings, these tests at present may prove too expensive and logis-
tically challenging as an alternative strategy in high-volume
settings.
OTHER APPROACHES TO REDUCING GBS-ASSOCIATED
MORBIDITY AND MORTALITY
Early recognition of neonatal sepsis
Administration of IAP does not eradicate the risk of early-onset
GBS disease. Furthermore, delay in administering IAP due to
factors such as late presentation to the labour ward, rapid deliv-
ery or misidentiﬁcation of risk factors/maternal GBS colonisa-
tion status can result in inadequate IAP cover. Early recognition
of the signs of neonatal sepsis and commencing treatment
promptly are crucial in preventing rapid invasive GBS disease
progression. Further studies are needed in LMIC settings.
Alternative routes of intrapartum antibiotic delivery
A randomised controlled trial to evaluate outpatient prenatal
oral amoxicillin versus placebo did not signiﬁcantly impact on
GBS vaginal colonisation at the time of delivery (p=0.20).55
Few studies have evaluated the pharmacokinetics or effectiveness
of IAP delivered by alternative routes, such as orally or intra-
muscularly. There could be a more feasible way to deliver intra-
partum antibiotics to at-risk women in labour outside of a
tertiary hospital setting in resource-limited countries and require
further evaluation.
Chlorhexidine
Chlorhexidine is a powerful mucous membrane disinfectant that
can result in suppression of maternal GBS, and therefore has
been proposed as a low-cost, easy-to-administer strategy in redu-
cing neonatal GBS sepsis. However, in a recent Cochrane review
of four trials of vaginal chlorhexidine there was no reduction of
EOD (sepsis and/or meningitis) or GBS pneumonia, although it
may reduce the GBS neonatal colonisation.19
GBS vaccine
A GBS vaccine, administered to mothers in pregnancy, could
provide protection to neonates against EOD and LOD via trans-
placental IgG antibody transfer to the fetus.16
Maternal vaccine-induced antibodies are transferred via the
placenta to the fetus through an active transfer process in the
second trimester of gestation onwards, providing protection to
the newborn for the ﬁrst few months of life.56 Transplacental
antibodies, as well as breast milk antibodies, may therefore
reduce both EOD and LOD.16 22 By augmenting pre-existing
maternal antibody levels, vaccination may also have the poten-
tial to prevent maternal intra-amniotic infections during preg-
nancy and postpartum endometritis,57 which could theoretically
impact against GBS-associated premature delivery and still-
births.58 However, in high HIV prevalence settings, the lower
immunogenicity of a trivalent polysaccharide–protein conjugate
vaccines in HIV-infected mothers (leading to lower transplacen-
tal antibody transfer) highlights the possible need for alternate
dosing schedules.59 60 A trivalent GBS polysaccharide–protein
conjugate vaccine has undergone phase II trials in South Africa
Table 1 Advantages and disadvantages of group B Streptococcus (GBS) carriage identification methods
Universal screening Risk-based approach RDT
Advantages Targeted prevention of GBS transmission from mother to
baby
Can monitor GBS carriage among women over time
Easier to implement—no laboratory set-up required
No requirement for mass antenatal screening
Cheaper to implement than universal screening or
RDTs
Potential to rapidly identify those at
highest risk of passing GBS to neonate
and can be done intrapartum
No requirement for mass antenatal
screening
Could be employed in preterm
deliveries.
Disadvantages Logistical challenges—relies on full laboratory set-up,
appropriate transport and storage conditions and timely
communication to clinical staff/pregnant women
Difficult to collect specimens at correct gestation in areas
where antenatal scans are not readily available
Results can take 18–48 hours—results may not be
available in time
GBS colonisation state is dynamic, and GBS status may
change from screening to delivery
Will miss 7–11% of preterm deliveries, which can
account for 32–38% of neonatal GBS EOD
Overlooks the biggest risk of GBS EOD, which is
presence of maternal GBS colonisation or GBS
bacteriuria
Potential to overtreat pregnant women with IAP who
do not carry GBS and miss those who may actually
have GBS colonisation
Will not prevent EOD in settings where there are
more home deliveries or in primary healthcare
settings with limited diagnostic and treatment
facilities
No samples collected—difficult to monitor true
effect on GBS carriage rate, transmission and any
development of antibiotic resistance
Cost issues: running the tests, storing
of reagents, training of staff in
performing tests and reading results
Clinical relevance of molecular assay
technique still needs to be quantified
EOD, early-onset GBS disease; IAP, intrapartum antibiotic prophylaxis; RDT, rapid diagnostic tests.
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and Malawi, and has the potential to offer cost-effective protec-
tion against GBS sepsis.59
CAN GBS PREVENTATIVE MEASURES BE PUT INTO
PRACTICE IN A RESOURCE-LIMITED SETTING?
The most promising strategy in reducing neonatal invasive GBS
disease is maternal vaccination; ﬁrst, it has the potential to
prevent both EOD and LOD; second, it could be made to be
cost-effective; and third, it may reduce GBS-related stillbirths
and premature delivery. However, the vaccine is still in develop-
ment, and it may be 10–15 years before it can be introduced
into routine care. Meanwhile, strategies to identify at-risk preg-
nant women and to implement IAP in resource-limited settings
need to be explored (table 1).
The ﬁrst step would be to consider either a universal screen-
ing or a risk-based approach. Both strategies ultimately rely on
the dependable availability of intravenous antibiotics and
adequately trained medical staff. IAP may be possible to imple-
ment in a tertiary or district hospital setting, but will prove very
difﬁcult at a primary healthcare setting, where diagnostic and
treatment facilities are limited, or in areas of high rates of home
births. These limitations may result in a less dramatic reduction
in EOD compared with high-income countries.
The advantage of universal screening at 35–37 weeks gesta-
tion is that it could identify those women with the highest risk
of invasive GBS disease, (ie, GBS colonisation near time of
delivery) and allow targeted treatment of GBS carriers with IAP.
However, there are logistical difﬁculties in implementing this
strategy in the resource-limited setting where antenatal care and
laboratory facilities may be sparse or lacking. Accurately target-
ing women at 35–37 weeks gestation is a challenge where
routine antenatal gestation calculation by ultrasound is not avail-
able. The transport, storage and processing of numerous speci-
mens, and communication of results to the pregnant women or
health professionals may be problematic.
On the other hand, a risk-based approach avoids mass screen-
ing, is cheaper to implement and could potentially achieve
similar reductions in EOD compared with universal screening.
Decision to treat can be made on admission, and therefore,
laboratory support is not required. However, this approach
potentially overlooks the main risk factor for EOD, which is
maternal GBS colonisation/bacteriuria. Up to 50% of women
with risk factors are not colonised with GBS,10 leading to
unnecessary administration of antibiotics, while women with no
risk factors in labour can still have babies with GBS disease.
Intrapartum GBS screening with rapid real-time PCR testing
was recommended by the Consensus Conference on GBS in
Europe in 2014.51 However, the cost to implement and require-
ments for appropriate reagent storage and supply would make
this a less attractive and practical alternative in the resource-
poor setting. A simple, cheap point-of-care test could improve
the timely implementation of IAP (ﬁgure 1).
Figure 1 Pathogenesis of neonatal group B Streptococcus (GBS) disease and target for intervention. IAP, intrapartum antibiotic prophylaxis; PROM,
prolonged rupture of membrane.
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A possible variation to the use of IAP is to revisit the efﬁcacy
of maternal intramuscular and high-dose oral antibiotics in
labour, which potentially circumvents the problem of delivering
intravenous antibiotics in primary healthcare or home settings.
The pharmacokinetics and drug concentration in utero need to
be further evaluated, and ultimately, if promising, these need to
be tested in controlled trials.
CONCLUSION
The development of measures to reduce the infectious causes of
neonatal mortality is critical, and supportive evidence is
urgently needed. Although vaccine development appears to be
the most feasible and cost-effective strategy to achieve long-term
solution, this may take several years to come to fruition.
Clinicians need to be able to recognise the early signs of neo-
natal sepsis and start the appropriate treatment promptly. Novel,
affordable alternative approaches to prevention should be
explored in parallel. Pharmacokinetics and pharmacodynamics
in utero of high-dose oral intramuscular antibiotics could be
revisited. Finally, critical barriers need to be addressed in select-
ing which prevention strategy is most suitable for the target
population and cost-effectiveness evaluated to reﬂect the avail-
able healthcare infrastructure. Once introduced into policy, it
will be essential that the appropriate surveillance is in place to
monitor uptake, and impact on neonatal mortality and anti-
microbial resistance.
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